VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens

VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens

VACCIMEL is a therapeutic cancer vaccine composed of four irradiated allogeneic human melanoma cell lines rationally selected to cover a wide range of melanoma tumor-associated antigens (TAA). We previously demonstrated that vaccination in the adjuvant setting prolonged the distant-metastasis-free s...

Full description

Bibliographic Details
Main Authors: Ibel Carri, Erika Schwab, Juan Carlos Trivino, Erika M. von Euw, Morten Nielsen, José Mordoh, María Marcela Barrio
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
whole cancer cell vaccine
allogeneic vaccine
VACCIMEL
neoantigen
melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1496204/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1496204/full

Similar Items